associated vasculitis

Related by string. * associating . Associating . ASSOCIATED . asso ciated . associ ated . Associated : Associated Press Via Acquire . Associated Press GfK poll . ASSOCIATED PRESS WRITER . Associated Press Ipsos poll . Associated Press GfK Poll . Associated Press writers / Vasculitis : ANCA vasculitis . ANCA vasculitis type . Vasculitis Foundation . vasculitis inflammation . vasculitis * *

Related by context. All words. (Click for frequent words.) 66 ANCA associated 62 metastatic malignant 62 colorectal carcinoma 62 Angiotensin II 61 Mouse Model 61 B Cell Lymphoma 61 pDC 61 methicillin susceptible Staphylococcus aureus 61 regulated kinase 61 SGPT 61 vapreotide acetate 61 SSc 61 Prolongs Survival 61 Hypertrophic 61 tissue transglutaminase 61 chronic eosinophilic leukemia 60 Leukemias 60 HLA DR4 60 Allogeneic 60 Pharmacokinetics PK 60 decarboxylase 60 Polymorphisms 60 Cardiac Troponin 60 Upregulation 60 mediated inhibition 60 squamous cell carcinoma SCC 60 Progenitor Cells 60 erythematosus 60 leiomyomas 60 Polymorphism 60 Diabetic Foot Ulcer 60 abacavir Ziagen 60 Oral Fingolimod 59 Vasculitis 59 metastatic neuroendocrine tumors 59 deoxy 59 HDAC Inhibitor 59 gene polymorphism 59 Oxidative 59 hypereosinophilic syndrome 59 neurological manifestations 59 Antitumor 59 PsA 59 thyroglobulin 59 pT2 59 LPS induced 59 ritonavir boosted 59 Castration Resistant Prostate Cancer 59 Lymphoid 59 Actinic Keratosis 59 situ CIS 59 denileukin diftitox 59 IN PATIENTS WITH 59 Adjuvant Chemotherapy 59 HBeAg negative 59 Leydig cell 59 fludarabine cyclophosphamide 59 Hematopoietic 59 CD#b 59 Chronic Pelvic Pain 59 Fludarabine 59 basal cell carcinoma BCC 59 Intravascular 59 Myelodysplastic Syndrome MDS 59 Macrophage 59 fibrin deposition 59 uricase 59 Bronchiectasis 59 ERalpha 59 Novel Oral 59 iNOS 59 Phase Ib Clinical Trial 58 Fas ligand 58 IL 1ß 58 Pelvic Organ Prolapse 58 Intracranial 58 adriamycin 58 induced apoptosis 58 CD# CD# 58 gastroduodenal 58 membranous nephropathy 58 primary aldosteronism 58 Alanine 58 Adjuvant Treatment 58 Complicated Skin 58 somatostatin analog 58 interleukin IL -# 58 MPGN 58 Systemic Sclerosis 58 hyperphenylalaninemia HPA due 58 Orally administered 58 Endothelial 58 cisplatin resistant 58 ^ sup #m 58 ara C 58 murine model 58 Chemokine Receptor 58 Chronic Hepatitis C 58 ABCB1 58 Alveolar 58 Adjunctive 58 Phase 2b Trial 58 severe neutropenia 58 Chronic Renal Failure 58 cytokines IL 58 Advanced Renal Cell 58 myasthenia gravis MG 58 bronchial hyperresponsiveness 58 Relapsing Remitting Multiple Sclerosis 58 Chemotherapy Induced 58 essential thrombocythemia ET 58 Basal Cell 58 cranial irradiation 58 Myelofibrosis 58 PEG IFN 58 Sezary syndrome 58 COL#A# 58 Diabetic Neuropathy 58 Dysplasia 58 HepG2 cells 58 tumor xenograft models 58 TIMP 1 58 cell adhesion molecule 58 1beta 58 Squamous Cell Carcinoma 58 Phosphorylation 58 Natalizumab 58 Antitumor Activity 58 Atypical Hemolytic Uremic Syndrome 58 Pegylated Liposomal Doxorubicin 58 Attenuates 58 Cytotoxicity 57 Angiotensin Converting Enzyme 57 Antigen Specific 57 Squamous 57 syngeneic 57 Idiopathic 57 stage IIIB 57 CC genotype 57 mineralocorticoid 57 allogeneic hematopoietic stem cell 57 Placebo Controlled Trial 57 enterococcal 57 Meets Primary Endpoint 57 Cardiotoxicity 57 ADAMTS# 57 Myelodysplastic Syndrome 57 Peginterferon 57 Cytogenetic 57 Cyclosporine 57 Secretase 57 Chronic Myelogenous Leukemia 57 Cyclophosphamide 57 functional polymorphism 57 T2DM 57 Systemic lupus erythematosus SLE 57 5FU 57 NMIBC 57 Phase 2a Clinical Trial 57 SGOT 57 Patients Receiving 57 occlusion CRVO 57 Ischemic 57 6 mercaptopurine 57 cytotoxic effects 57 colorectal adenoma 57 polycythemia vera essential thrombocythemia 57 Clusterin 57 allogeneic hematopoietic cell 57 J Am Soc 57 Bosentan 57 Immune Mediated 57 phorbol 57 Elevated serum 57 Coronary Arteries 57 Non Alcoholic Steatohepatitis 57 anterior uveitis 57 PLA2 57 papillary renal cell carcinoma 57 biologic DMARD 57 thymidine kinase 57 4mg/kg 57 Leucovorin 57 bleomycin 57 autosomal dominant polycystic kidney 57 Orally Active 57 mycosis fungoides 57 isotypes 57 FVIII 57 CYP #D# 57 CLINICAL PHARMACOLOGY 57 Nucleoside 57 Lenalidomide 57 tryptase 57 Papillary 57 anticholinergic agents 57 relapsing multiple sclerosis 57 TIMP 57 biochemical relapse 57 Rheumatoid 57 cisplatin gemcitabine 57 Follicular Lymphoma 57 promoter polymorphism 57 Invasive Fungal Infections 57 activating mutation 57 Interferon Alfa 57 ovarian carcinoma 57 null mice 57 novel VDA molecule 57 rheumatoid factor 57 paraneoplastic 57 Zorbtive TM 57 Posaconazole 57 Anthracycline 57 serum antibodies 57 mimetic peptide 57 Nebulized 57 familial amyloidotic polyneuropathy FAP 57 selective modulator 57 Type IIa 57 baseline LDH 57 vitro cytotoxicity 57 colorectal liver metastases 57 Proteasome 57 antiproliferative effects 57 replicase 57 Inhaled AAT 56 Phase 2b Clinical Trial 56 Acute Renal Failure 56 mediated apoptosis 56 Myeloid 56 dasatinib Sprycel ® 56 TO AVOID PREGNANCY WHILE 56 EGFR HER2 56 Synuclein 56 Acute Ischemic Stroke 56 Autologous Stem Cell Transplantation 56 Chemoradiation 56 Nilotinib 56 Tigecycline 56 azacytidine 56 Oesophageal 56 BPS IC 56 eNOS 56 fluconazole resistant 56 Carcinomas 56 Chronic Kidney 56 K#R [002] 56 Controlled Trial 56 sensory neuropathy 56 Humanized Anti 56 Diffuse Large B 56 hematological parameters 56 Paraplatin ® 56 dose dependently 56 myelodysplastic myeloproliferative diseases 56 Antiviral Therapy 56 neovascularisation 56 Adenoviral 56 Zollinger Ellison syndrome 56 xenograft model 56 pleural fluid 56 coagulopathy 56 immunomodulatory therapy 56 atherothrombotic 56 Relapsing Multiple Sclerosis 56 pancreatic islet cell 56 pan HDAC inhibitor 56 arthritis PsA 56 diabetes mellitus DM 56 Soft Tissue Sarcoma 56 leukocytosis 56 receptor blocker 56 annexin V 56 Hormone Refractory Prostate Cancer 56 relapsed MM 56 Pemetrexed 56 orally administered inhibitor 56 fosbretabulin 56 mitoxantrone chemotherapy 56 Ventricular Tachycardia 56 Chronic Fatigue Syndrome CFS 56 Kinase Inhibitor 56 Protease Inhibitors 56 immunoreactive 56 transgene expression 56 Nephrol 56 FUSILEV enhances 56 Left Ventricular Dysfunction 56 included exfoliative dermatitis 56 Granted Orphan Drug 56 AST ALT 56 Improves Outcomes 56 oral candidiasis 56 subependymal giant cell 56 Glioblastoma Multiforme 56 Dysregulation 56 pulmonary hypertension PH 56 selectively binds 56 Plaque Psoriasis 56 inducible nitric oxide synthase 56 kidney urologic 56 Cell Lymphoma 56 Janus kinase 56 renal allograft 56 Beta Amyloid 56 Pancreatic 56 chloride secretion 56 complement inhibitor eculizumab 56 Candida infection 56 vinca alkaloid 56 N acetyl 56 Knee Osteoarthritis 56 Chronic Sinusitis 56 #:#-# [031] 56 urothelial 56 Embolization 56 ATTR CM 56 Fungal Infections 56 transduced 56 Neovascular Age Related Macular 56 CTAP# 56 Idiopathic Pulmonary Fibrosis 56 erlotinib Tarceva ® 56 Fluorouracil 56 TRAIL R1 56 transthyretin amyloidosis 56 fluorescein angiography 56 Irritable Bowel 56 systemic autoimmune 56 Inhibits 56 Patients Treated With 56 Gorlin syndrome 56 basiliximab 56 EP4 56 Interferon beta 1a 56 Left Ventricular 56 interstitial brachytherapy 56 microsomal 56 TREATMENT OF 56 epoetin alpha 56 Renal Artery 56 Corynebacterium 56 rs# [004] 56 Hemolysis 56 Ranolazine 56 Fingolimod 56 recurrent glioblastoma multiforme 56 Lubiprostone 56 Chronic Heart Failure 56 liver histology 56 renal tumors 56 endocrine therapies 56 voriconazole 56 Neoplasms 56 selective inhibition 56 pancreatic adenocarcinoma 56 Pegylated Interferon 56 LV ejection fraction 56 gastrointestinal stromal tumor 56 Improves Survival 56 #p# [003] 56 Refractory Hodgkin Lymphoma 56 cutaneous lesions 55 experimental autoimmune encephalomyelitis 55 neovascularization 55 Severe Sepsis 55 steroidogenesis 55 endoluminal stent graft 55 BCG refractory carcinoma 55 transaminase 55 Systemic Lupus Erythematosus SLE 55 artery stenosis 55 1alpha 55 Glycosylation 55 monogenic 55 Gleevec resistant 55 Granulocyte Colony Stimulating Factor 55 severe oral mucositis 55 Receptor Antagonists 55 polyneuropathy 55 muscarinic receptors 55 lysophosphatidic acid 55 immunofluorescence microscopy 55 liposomal formulation 55 JAK2 enzyme 55 meropenem 55 Retreatment 55 clinicopathological 55 monocyte chemotactic protein 55 atrophic gastritis 55 thymoma 55 AA Amyloidosis 55 Tyrosine Kinase Inhibitors 55 Immune Responses 55 Hematopoietic Stem Cells 55 Adenoma 55 R Saizen R 55 FDA APPROVES 55 Treating Chronic 55 vasoactive 55 nucleoside analog 55 euthyroid 55 idebenone 55 cis retinoic acid 55 potently inhibited 55 topically administered 55 fibrosarcoma 55 glycopeptide 55 CP CPPS 55 oral prodrug 55 Receives Orphan Drug Designation 55 receptor tyrosine kinase inhibitor 55 cytokeratin 55 ,#,# [002] 55 Exacerbations 55 GORE TAG Device 55 antiangiogenic agent 55 Supplemental Figure 55 Placebo Controlled Study 55 BCG refractory 55 Differential diagnosis 55 TNF Tumor Necrosis Factor 55 refractory chronic lymphocytic 55 Oral Mucositis 55 Reductase 55 Cortical 55 PAOD 55 TNFalpha 55 Drug Candidate 55 Kinoid 55 adrenocorticotropic hormone 55 Pegylated 55 Trigeminal Neuralgia 55 Intravenous immunoglobulin 55 somatostatin 55 myeloperoxidase 55 aminotransferase 55 dimeglumine 55 hepatocellular carcinomas 55 progressive neurodegenerative disorder 55 humanized monoclonal 55 proto oncogene 55 immunostaining 55 grade cervical intraepithelial 55 gastrointestinal stromal tumors GIST 55 5 Fluorouracil 55 Single Dose 55 Metastatic Prostate Cancer 55 intracranial hemorrhage ICH 55 osteoinductive 55 SHPT 55 hyperplasia BPH 55 atypical Hemolytic Uremic Syndrome 55 metastatic gastric 55 dihydrochloride 55 histone deacetylase inhibitor 55 cefotaxime 55 acetonide FA 55 plasminogen activator inhibitor 55 Carcinoma 55 radiosensitivity 55 Phase 2b Study 55 Pharmacologic 55 Novel Inhibitor 55 Aneurysm Repair 55 hepatorenal syndrome 55 melphalan prednisone 55 Sjögren syndrome 55 Hepatic 55 intraventricular 55 MDR1 55 Melphalan 55 ileal 55 intraperitoneal injection 55 airway hyperresponsiveness 55 Inflammatory Pain 55 cyclin dependent kinase inhibitor 55 NS#/#A protease 55 NF kappaB activation 55 leukocyte count 55 proliferative retinopathy 55 E. faecalis 55 TSH receptor 55 Histologic 55 granulomatous 55 EGFR TKI 55 MELAS 55 Toxicities 55 Neutrophil 55 inhibitor RG# 55 peripheral blood mononuclear 55 Familial Adenomatous Polyposis FAP 55 Capecitabine 55 Inhaled Corticosteroids 55 cinacalcet 55 potent inhibition 55 epithelial tumors 55 HGPIN 55 AT1R 55 Linezolid 55 Hcy 55 plasma renin activity 55 Erythropoietic 55 alanine aminotransferase ALT 55 gefitinib Iressa 55 adalimumab Humira 55 uM 55 cystic fibrosis chronic pancreatitis 55 Ejection Fraction 55 Advanced Solid Tumors 55 promoter methylation 55 NAGS deficiency 55 CsA 55 glycosyltransferase 55 GSTP1 55 Decitabine 55 Langerhans cell histiocytosis 55 Severe Asthma 55 55 extra articular 55 Hemodialysis Patients 55 Cystic 55 trans retinoic acid 55 Spasticity 55 Tyrosine Kinase 55 Flu Cy 55 Advanced Melanoma 55 intratumoral 55 sulfasalazine 55 thalidomide Thalomid 55 thyrotropin 55 doxorubicin cyclophosphamide 55 Relapsed Refractory 55 B. burgdorferi 55 pT3 55 crossclamp 55 Prospective Randomized 55 haematologic 55 TNF α 55 urothelial carcinoma 55 amikacin 55 somatostatin analogue 55 IFN α 55 paroxysmal AF 55 Sydenham chorea 55 Microalbuminuria 55 mRNA expression 55 Interferon alpha 55 SensoLyte ™ 55 busulfan 55 Stereotactic Body Radiation Therapy 55 pmol L 54 mineralocorticoid receptor 54 idiopathic PAH 54 Adenocarcinoma 54 seropositivity 54 erythropoietic 54 carcinoembryonic antigen 54 solar keratoses 54 Investigational Treatment 54 hyperammonemia 54 murine models 54 Autoimmune Diseases 54 pemphigus vulgaris 54 Unresectable 54 Camptosar ® 54 Psoriatic arthritis 54 serum phosphate 54 TRUS 54 MDA MB 54 hypercalcaemia 54 Diabetic Foot Ulcers 54 drug zotarolimus 54 platelet inhibitor 54 hepatoma 54 antiproliferative activity 54 ALA PDT 54 J Am Acad 54 sulfonamide 54 ^ Tc 54 neutropenia thrombocytopenia 54 Metastatic Colorectal Cancer 54 deletion 5q 54 immunofluorescence 54 Nat Clin Pract 54 allelic variants 54 F FDG PET 54 virus HCV 54 Interferon alfa 54 TMPRSS2 ERG 54 Annexin 54 Hsp# Inhibitor 54 vWF 54 Inosine 54 PBMCs 54 Angioedema 54 NS5B polymerase 54 Myasthenia gravis 54 PPARgamma 54 Quantitation 54 malignant lymphomas 54 Adjunctive Therapy 54 CYP#A# substrate 54 post transplant lymphoproliferative 54 Patients Treated 54 Conjugated 54 Eluting Stent 54 Abstract Number 54 Lupus nephritis 54 generation purine nucleoside 54 E selectin 54 prostate cancer CaP 54 docetaxel Taxotere ® 54 Exacerbation 54 induced cytotoxicity 54 Tumor Necrosis Factor 54 acute humoral rejection 54 carmustine 54 Treated Patients 54 hypertrichosis occurred 54 ST Segment Elevation 54 tiuxetan 54 Pharmacokinetic Study 54 anti angiogenic agent 54 Anti Tumor 54 beclomethasone dipropionate 54 Long Term Efficacy 54 reflux esophagitis 54 multikinase inhibitor 54 papillomas 54 SPRYCEL ® 54 Taxol ® 54 antinuclear antibody 54 â ‰ ¥ 54 Anti VEGF 54 thyroid hormone receptor 54 Score TOS 54 Tumor Cell 54 Sevelamer 54 Cutaneous T 54 acute GvHD 54 targeted antifolate 54 Alkaline Phosphatase 54 serum ALT 54 leukotriene 54 Chronic lymphocytic leukemia 54 lymphoproliferative disorders 54 Esophagitis 54 LHON 54 Chemotherapy induced 54 histone deacetylase HDAC inhibitor 54 triiodothyronine 54 prostanoid 54 CIMZIA ™ 54 Mantle Cell Lymphoma 54 Catenin 54 Hypertensive Patients 54 Randomised 54 pancreatic ducts 54 cytotoxin 54 Clinical Efficacy 54 selective adenosine 54 Metastatic Melanoma 54 Tumor Response 54 RhuDex ™ 54 ergot alkaloids 54 plasmid encoding 54 carboxypeptidase 54 Proc Am Soc 54 chronic idiopathic thrombocytopenic purpura 54 proliferative diabetic retinopathy 54 Tubulin 54 chronic granulomatous disease 54 Duodenal 54 hypertrophic scars 54 Fibromyalgia syndrome 54 LPA1 receptor 54 Prostaglandin 54 Microspheres 54 Estrogen Receptor 54 Doxil ® 54 Contrast Agents 54 adrenoceptor 54 cyclophosphamide methotrexate 54 SSc patients 54 Am J Cardiol 54 histologically confirmed 54 P. acnes 54 heme oxygenase 1 54 Carotid 54 fluticasone propionate FP 54 Well Tolerated 54 Assay Kit 54 depsipeptide 54 chronic thromboembolic pulmonary 54 renal scarring 54 PSA nadir 54 nonbacterial prostatitis 54 κ 54 protein tyrosine phosphatase 54 polycythemia vera PV 54 PON1 gene 54 headache abdominal pain 54 Solid Tumors criteria 54 renal artery stenting 54 Anaplastic 54 Nephrogenic 54 administered subcutaneously 54 Triamcinolone 54 rs# [001] 54 hydroxylase 54 Parenteral Nutrition 54 immunoreactivity 54 urate oxidase 54 Transdermal Patch 54 acute myeloid 54 selective agonist 54 pulmonary fungal infections 54 SensoLyte ® 54 beta 1a 54 Late Breaker 54 By JENNIFER LEARN 54 Liposomal 54 medullary thyroid carcinoma 54 Recombinant Human 54 chimeric monoclonal antibody 54 isomerase 54 HCV Genotype 54 Subcutaneous 54 refractory colorectal cancer 54 aminotransferases 54 pouchitis 54 experimental allergic encephalomyelitis 54 choroidal neovascularization 54 nitrotyrosine 54 T1c 54 intrahepatic 54 Minimally Invasive Treatment 54 Squalamine 54 hepatic enzymes 54 clotrimazole 54 Atrial Flutter 54 Electrical Stimulation 54 gastrointestinal stromal tumors GISTs 54 symptomatic benign prostatic 54 hypercalcemia 54 TTR amyloidosis 54 antithyroid 54 Secondary Hyperparathyroidism 54 Platinol ® cisplatin 54 Anticancer Drug 54 Associated Adipose Redistribution 54 Interstitial cystitis 54 Calcification 54 constitutively expressed 54 prospective multicenter study 54 potent antiproliferative 54 hemodilution 54 EGFP 54 Dasatinib 54 intact parathyroid hormone 54 JAK2 Inhibitor 54 phospholipase 54 immunocompetent patients 54 Unfractionated Heparin 54 plasma uric acid 54 autosomal recessive disease 54 Novel Compound 54 Respiratory Virus 54 Patients Undergoing 54 P#Y# [001] 54 INDUSTRY ASSESSMENTS 54 Chronic Rhinosinusitis 54 Resection 54 Peginterferon Alfa 2a 54 Pemphigus 54 Wafer polifeprosan 54 Urethral 53 Teriflunomide 53 MAGE 53 Keratitis 53 favorable pharmacokinetic profile 53 malignant lymphoma 53 Hematological 53 Initiate Clinical Trial 53 GW# [003] 53 pelvic lymphadenectomy 53 orthotopic 53 Carbamazepine 53 Etanercept 53 zoledronate 53 iobenguane 53 Adjuvant Therapy 53 Mg Uk 53 costimulatory molecules 53 Irinotecan 53 ESR1 53 Protein Kinase C 53 Endometrial Cancer 53 lactate dehydrogenase LDH 53 #F FDG 53 GHRH 53 NSAID induced GI 53 Antiviral Activity 53 adrenomedullin 53 Neurodegenerative diseases 53 Aurora Kinase 53 Leukotriene 53 vulvovaginal atrophy 53 BH4 deficiency 53 CTEPH 53 R bisoprolol Euthyrox 53 Risk Stratification 53 diabetic gastroparesis 53 macular edema secondary 53 R lenalidomide 53 prucalopride 53 Adefovir 53 leukemia CLL 53 creatine kinase CK 53 clinicopathological features 53 phosphoprotein 53 Predict Response 53 agalsidase alfa 53 Taclonex R 53 Atopic 53 HLA DRB1 * 53 efalizumab 53 Lp PLA 2 53 HbF 53 Protease Inhibitor 53 Alpha lipoic acid 53 Onychomycosis 53 lactate dehydrogenase 53 synovial fibroblasts 53 corrected QT interval 53 Antiangiogenic 53 neuropathologic 53 PEGylated interferon beta 1a 53 Otitis Media 53 targeted radiotherapeutic 53 aspartate aminotransferase 53 NMDA antagonists 53 N methyl 53 TGF beta1 53 IVIG therapy 53 #β estradiol 53 receptor inhibitor 53 Malignant Glioma 53 unstable angina UA 53 Dilated Cardiomyopathy 53 Radiofrequency Ablation 53 Double Blind Randomized 53 trimethoprim sulfamethoxazole 53 covalently linked 53 RRM1 53 Microplasmin 53 variant allele 53 albumin excretion rate 53 flavopiridol 53 CLL SLL 53 IL6 53 intravesical instillation 53 Ki# 53 Contrast Enhancement 53 Metastatic Renal Cell Carcinoma 53 ribavirin RBV 53 Insulin Resistance 53 tyrosine kinase inhibitors TKIs 53 Renal Cell Carcinoma 53 SYN# 53 kidney allograft 53 lymphoid malignancies 53 ATTR 53 chemokine receptor 53 Candida infections 53 Immunosuppressant 53 Atopic Dermatitis 53 Phase IIa Clinical Trial 53 chronic prostatitis 53 Androgen Receptor 53 Acute myeloid leukemia 53 tyrosine phosphorylation 53 Hematologic 53 Interferon Gamma 53 Contrast Agent 53 receptor subtypes 53 capillary leak 53 Is Well Tolerated 53 serum TSH 53 HLA A2 53 Basal Cell Carcinoma 53 Adrenergic 53 pertussis toxin 53 restenotic lesions 53 inotropic 53 5HT 53 Pivotal Study 53 immune globulin intravenous 53 chlorambucil 53 multicentric 53 levodopa induced 53 aggrecan 53 Th2 cytokines 53 dipeptide 53 effector function 53 myelofibrosis polycythemia vera 53 cheilitis 53 Azacitidine 53 ACTH 53 Cellular Immunotherapy 53 Severe Primary IGFD 53 leukotriene B4 53 ganciclovir 53 extracranial 53 leucopenia 53 mCi 53 Multiple Myeloma MM 53 oxacillin 53 serologically active systemic lupus 53 hematopoietic cell 53 Hypertriglyceridemia 53 interleukin IL 53 Renal Physicians 53 Blepharospasm 53 histological subtype 53 DOXIL 53 Oncogenic 53 Epratuzumab 53 downstream effector 53 sorafenib Nexavar 53 Phase III Clinical Trial 53 Immune Thrombocytopenic Purpura ITP 53 β blockers 53 μg ml 53 Randomized Phase 53 Adult Stem Cell Therapy 53 intracellular accumulation 53 Ferritin 53 FDG PET imaging 53 autologous hematopoietic stem cell 53 radiotherapy induced 53 cytotoxicity 53 ADP receptor antagonist 53 Monotherapy 53 unstable angina pectoris 53 Bosutinib 53 Anti Tumor Activity 53 eosinophil count 53 interstitial cystitis IC 53 pregabalin Lyrica 53 dinucleotide 53 cirrhosis liver failure 53 CYP# [002] 53 FOLFOX6 53 Fludara ® 53 Susceptibility Testing 53 saline placebo 53 assay detects 53 ALT elevations 53 Hormone Receptor Positive 53 CYP #A# 53 elevated creatinine 53 ULORIC 53 Cell Transplant 53 Hepatitis C Genotype 53 BCL2 53 cidofovir 53 gemcitabine Gemzar ® 53 alefacept 53 airway hyper responsiveness 53 autoantibody 53 Preclinical Study 53 BENICAR 53 autoimmune thyroid 53 MYLOTARG 53 lupus scleroderma 53 Pgp 53 primary hyperparathyroidism 53 Nat Genet 53 prostate carcinoma 53 aspartate aminotransferase AST 53 microvessel density 53 sunitinib Sutent 53 cardiac allograft vasculopathy 53 idiopathic Parkinson disease 53 Multiple Ascending Dose 53 Anesth 53 CD4 + CD# 53 μmol L 53 Mass Spectrometers 53 neoadjuvant 53 budesonide foam 53 Treatment Outcome 53 N Acetyl 53 Nonspecific 53 Overactive Bladder 53 Cytotoxic

Back to home page